

**\*\*\*Preliminary Program - Times and poster numbers may change\*\*\***



**IBCN Annual Meeting - 2025  
October 9th – October 11th  
Munich, Germany  
Hilton Munich City**

**Program Co-Chairs:  
Madhuri Koti, DVM, MVSc., PhD  
Kent W. Mouw, MD, PhD**

# IBCN2025

October 9 – October 11

Munich, Germany

---

## A special thank you to our 2025 meeting industry sponsors:

### Platinum:

Bristol Myers Squibb  
CG Oncology  
Cepheid  
EnGene  
ImmunityBio  
Johnson & Johnson  
Pfizer

### Gold:

Photocure

### Silver:

Merck [MSD]



---

M U N I C H

We would like to thank the following IBCN members for  
reviewing abstracts for the 2025 Annual Meeting:

Florestan Koll  
Isabelle Bernard-Pierrot  
Janet Kukreja  
Jeremy Teoh  
Michèle Hoffmann  
Nagireddy Putluri  
Rouf Banday  
Timo Nykopp

# IBCN2025

October 9 – October 11

Munich, Germany

## **THURSDAY OCTOBER 9th, 2025**

### **19:00 Welcome Reception - Hofbräukeller**

The traditional IBCN welcome “get together”. Drinks will begin at 7 pm followed by a buffet dinner at 8 pm.

#### **Hofbräukeller**

Innere Wiener Straße 19,  
81667 München, Germany

## **FRIDAY OCTOBER 10th, 2025**

\*\*\*Breakfast on your own\*\*\*

### **Introduction**

07:30	Registration Check-In	
08:00	Welcome to IBCN	Peter Black
08:05	Welcome to Munich	Roman Nawroth

### **Abstract Session I: Novel approaches to bladder cancer screening and treatment**

Co-Chairs: B. Szabados and I. Bernard-Pierrot

08:15	Real World Evaluation of the GALEAS Bladder Urine Test	Douglas Ward
08:25	Reclassifying risk with a generalizable molecular classifier for aggressive tumors in low-grade bladder cancer	Ewan Gibb
08:35	ENLIGHTED phase 3 study: Interim Results of Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic therapy (VTP) in the treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)	Gautier Marcq
08:45	Preliminary results from LEGEND: a Phase 2 study of detalimogene voraplasmid, a novel, investigational, non-viral genetic medicine for high-risk non-muscle invasive bladder cancer (NMIBC)	Wassim Kassouf
08:55	Artificial Intelligence and Multiparametric MRI Predict Clinical Outcomes to Neoadjuvant Immunotherapy in Patients with Muscle Invasive Bladder Cancer (MIBC) Undergoing Radical Cystectomy	Andrea Necchi
09:05	Q&A	Co-Chairs

### **09:15 - 09:30 Break**

### **Keynote Speaker I**

09:30	Bytes to Bedside: Insights and opportunities offered by whole genome sequencing	Serena Nik-Zainal
10:00	Discussion	Sita Vermeulen
10:15	Breakout Session Overview	Peter Black

### **10:20 - 10:45 Break**

## 23<sup>th</sup> Meeting of the IBCN

October 9 – October 11, 2025

Munich, Germany

### 10:45 – 12:45 Industry Meets IBCN – Breakout Sessions

Partner	Topic	Facilitator	Room #
Bristol Myers Squibb	TBD	TBD	TBD
CG Oncology	TBD	Peter Black, Colin Dinney	TBD
Cepheid	TBD	TBD	TBD
EnGene	TBD	TBD	TBD
ImmunityBio	TBD	TBD	TBD
Johnson & Johnson	TBD	TBD	TBD
Pfizer	TBD	Ashish Kamat, TBD	TBD

### 12:45 - 14:00 Lunch and Poster Viewing

#### IBCN Speaker

14:00	Predictive biomarkers: where do we stand?	David McConkey
14:30	Discussion	Roman Nawroth

### Abstract Session II: -omic profiling of bladder cancer

Co-Chairs: G. Vandekerkhove and R. Banday

14:45	Genomic Landscape of Bladder Pure Squamous Cell Carcinoma Versus Urothelial Carcinoma of the Bladder	Saad Atiq
14:55	Spatial Profiling of the Tumor Microenvironment in Plasmacytoid Urothelial Carcinoma	Kathryn Gessner
15:05	Genomic characterization of upper urinary tract urothelial carcinoma and clonal evolution of intravesical recurrence	Alberto Nakauma-González
15:15	Tracking heterogeneity and the trajectory of neoplastic disease progression in bladder cancer subtypes using spatial transcriptomics and liquid biopsy	De Hahn
15:25	Bulk and spatial transcriptional signatures of durable response from Durvalumab-based therapy in BCG-unresponsive (BCG-U) non-muscle invasive bladder cancer (NMIBC)	Roy Elias (Virtual) Noah Hahn
15:35	Q&A	Co-Chairs
15:45	Closing words and poster session introduction	Roman Nawroth

### 16:00 - 18:00 Poster Session “Happy Hour”

Location: TBD

### 20:00 IBCN Gala

#### Munich Residenz

Residenzstraße 1  
80333 München, Germany

# 23<sup>th</sup> Meeting of the IBCN

October 9 – October 11, 2025

Munich, Germany

## **SATURDAY OCTOBER 11th, 2025**

\*\*\*Breakfast on your own\*\*\*

### **IBCN – General Assembly**

08:00	General Assembly Session	Members Only
-------	--------------------------	--------------

### **Session I: Spatial Biology**

Chair: M. Koti

09:00	Multimarker exploration of the tumor microenvironment in patients with high-risk NMIBC using spatial proteomics	Trine Strandgaard
09:20	Spatial distribution of molecular features in tumors with divergent chemotherapy responses	Gottfrid Sjö Dahl
09:40	Geographies of resistance: How tumor niches silence immunity and fuel growth	Amir Horowitz

### **10:00 - 10:10 Break**

### **Keynote Speaker II**

10:10	New Insights Into BCG, the First Immunotherapy of Cancer	Michael Glickman
10:40	Discussion	Lars Dyrskjöt

### **Session II: Novel Clinical Trial Design and Updates**

Chair: R. Seiler

10:55	NMIBC clinical trials: landmark reports from 2025	Wassim Kassouf
11:15	Clinical trials in urothelial cancer: moving out of the platinum era	Michiel Van der Heijden
11:35	Challenging systems, pathways, and dogma: results of the BladderPath trial	Richard Bryan

### **11:55 - 12:05 Break**

### **Abstract Session III: From tumor initiation to therapeutic discovery**

Co-Chairs: C. Le Magnen and F. Koll

12:05	The innate urothelial response to BK Polyomavirus infection drives interferon-mediated APOBEC3A mutational damage.	George Hatton
12:15	Integrated transcriptomic and spatial immunophenotyping reveals T cell exhaustion and B cell associated immunosuppressive niches in BCG-Unresponsive NMIBC	Kartik Sachdeva
12:25	Expanding the treatment Landscape of FGFR-Targeted Therapy in Bladder Cancer: Integrative Genomic and Functional Profiling of Patient-Derived Organoids	Vandana Solanki
12:35	Characterization of Growth Differentiation Factor 15 (GDF-15) as a Therapeutic Target in Urothelial Carcinoma	Florestan Koll
12:45	Phenotypic screening of bladder cancer cultures to find toxic natural products	Nagireddy Putluri
12:55	Q&A	Co-Chairs

**13:00 - 13:50 Lunch and Poster Viewing****Session III: Mechanisms of Therapeutic Resistance**

Chair: K. Mouw

13:50	Exploring Pathways of Resistance to Immune-Mediated Cell Death in Bladder Cancer	Morgan Roberts
14:10	Mechanisms of resistance to antibody-drug conjugates	Niklas Klumper
14:30	The role of enhancer dysfunction in urothelial tumorigenesis	Yu Chen

**Abstract Session IV:  
Moving towards clinically tractable tumor classification**

Co-Chairs: J. Damrauer and V. Packiam

14:50	An Immunohistochemical Panel for Predicting Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer	Ioana-Maria Mihai
15:00	Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy	Chiara Mercinelli
15:10	Real-time single-sample Lund Taxonomy tumor classification in the prospective Swedish UROSCANSEQ study	Pontus Eriksson
15:20	Artificial Intelligence Predicts Molecular Subtypes and Outcomes in Muscle-Invasive Bladder Cancer from Whole Slide Images	Jacqueline Fontugne
15:30	Leveraging Machine Learning to Identify Interpretable Histopathologic Features in Muscle-Invasive Bladder Cancer for Neo-Adjuvant Treatment Response Prediction	Nikolay Alabi
15:40	Q&A	Co-Chairs

**Awards & Closing Remarks**

15:45	Awards Presentation	Peter Black
15:55	Welcome to Toronto - IBCN 2026	Alexandre Zlotta
16:00	Adjourn	



Poster #	Abstract Title	Presenter
1	Genomic Landscape of Bladder Pure Squamous Cell Carcinoma Versus Urothelial Carcinoma of the Bladder	Atiq, Saad
2	Urinary TERT Promoter Mutations as a Robust Non-Invasive Biomarker for Predicting Bladder Cancer Recurrence and Progression	Avogbe, Patrice Hodonou
3	Concordance Between Tumor Genomic Profiling and ctDNA for Recurrence Risk in Muscle-Invasive Bladder Cancer	Aydogdu, Can
4	Urinary minimal residual disease testing identifies early recurrence and monitors BCG response in patients with high-risk non-muscle-invasive bladder cancer	Bahlburg, Henning
5	Cx32 status predicts mesenchymal acquisition in luminal MIBC with implications for subtyping	Baker, Jennifer
6	APOBEC-Driven CNV–SNV Conflict Shapes Tumor Immune Visibility	Banday, Rouf
7	Gene regulatory Network inference reveals p63 as a key protumoral master regulator in FGFR3-mutated luminal bladder cancers.	Bernard-Pierrot, Isabelle
8	Time Modeling of Mutational Signature of Bladder Cancer Development from Mucosal Field Effects on the Whole-Organ Scale	Czerniak, Bogdan
9	Impact of Molecular Subtyping and Immune Signatures on Pathological Response following Neoadjuvant Nivolumab, Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer	de Jong, Joep
10	Investigation of carcinogenic effects of polystyrene microplastic on human bladder cancer cells	Dewala, Sahab Ram
11	All-stage bladder cancer proteomics map tumor specificity and identify prognostic and predictive subtypes	Dressler, Franz
12	Disrupting the PDGFR_ $\alpha$ -driven progression signature leads to enhanced control of bladder cancer	El Ahanidi, Hajar
13	Hexaminolevulinat stimulates senescence and induces PD-L1 expression in muscle-invasive bladder cancer cell lines	Gakis, Georgios
14	Investigating Combination Therapies for Non-Muscle-Invasive Bladder Cancer Using Advanced 3D Human Cell-Based Preclinical Models	Gao, Jinhui
15	Outlining The Role of Hypoxia in Bladder Cancer Dedifferentiation and Progression	Garven, Andrew
16	Beyond Viral Mimicry: Transposable Element Expression Defines Prognostic Stress-Response Phenotypes in Bladder Cancer	Garven, Andrew
17	Vitamin D receptor regulates the invasive capacity of bladder cancer cells through interactions with AKT kinases	Günes, Cagatay
18	Pten loss promotes p53 loss of heterozygosity and immune escape in a novel urothelial organoid model with p53 missense mutations	Hamada, Akihiro
19	Long-Term Oncologic Outcomes and Extracellular Vesicle Signatures in Bladder Cancer	Handke, Analena
20	BEST-PATH: Scalable Research Training for Undergraduates in Bladder Cancer Pathology and Pathology Report Analysis	Harding, Allison
21	Characterization of the Heterogeneity of Antibody-Drug Conjugate Targets in Bladder Cancer on Single-Cell Level	Hauser, Lena Marie
22	Multi-level characterization of new patient-derived bladder cancer models	Herek, Paula
23	Augmenting PARP inhibitor efficacy in urothelial cancer cells by combination with a BET inhibitor	Hoffmann, Michèle J
24	Exploring Bladder Cancer Research Priorities - aligning science with patient need	Humayun-Zakaria, Nada
25	Spatial Assessment of FGFR3 Protein Expression and T-cell Infiltrations Reveals Distinct Distribution Patterns in Upper Tract Urothelial Carcinoma and Normal Urothelium	Iwata, Tomoko
26	Development of 3D bladder cancer organoid models to investigate the efficacy of cancer immunotherapies.	Jennings, Vicki
27	Prevalence and Clinical Characteristics of Oligometastatic Urothelial Cancer in British Columbia	Kahn, Laiba
28	Using the Computational Histologic Artificial Intelligence (CHAI) platform to predict FGFRm status in bladder cancer	Kiedrowski, Lesli
29	Investigating chronic inflammation induced accelerated immune aging and response to Bacillus Calmette Guérin immunotherapy in non-muscle invasive bladder cancer	Koti, Madhuri
30	Disparities in guideline-concordant care and outcomes in non-muscle invasive bladder cancer: The impact of age and socioeconomic marginalization in a universal healthcare system	Kwong, Jethro

# IBCN2025

October 9 – October 11

Munich, Germany

Poster #	Abstract Title	Presenter
31	The role of event-free survival as a surrogate outcome in the BCG-naïve and BCG-exposed NMIBC setting	Kwong, Jethro
32	Leveraging patient-derived organoids to identify novel therapeutic vulnerabilities in bladder cancer	Le Magnen, Clementine
33	Radiogenomic Analysis of Muscle-Invasive Bladder Cancer using CT-based Texture Analysis	Lerner, Seth
34	MNU carcinogen rat model of NMIBC: a robust platform for uncovering single-cell immune complexity following BCG immunotherapy	Lombardo, Kara
35	Exploring cisplatin-gemcitabine's impact on GLUT1 and KDM3A expression patterns in bladder cancer	Macedo Silva, Catarina
36	Microbiome-Based Predictors of Response to Immune Checkpoint Inhibitors in Urological Cancers	Magyar, Balázs
37	A universal molecular map of bladder cancer: from cell lines in vitro to tumors and back using co-regulatory networks	Marcq, Gautier
38	Biologically-informed machine learning identifies a new clinically-actionable MIBC subgroup with NRF2 overactivity	Mason, Andrew
39	Response Profiling of Enfortumab Vedotin and Sacituzumab Govitecan Using Patient-Derived Organoids: A Step Closer to Precision Oncology	Melzer, Michael Karl
40	The Genomic Landscape of Bladder Cancer: Insights from Copy Number Alteration Profiles	Moreno-Oya, Ane
41	Establishment of an innovative, human stem cell-based culture model to investigate molecular carcinogenesis of urothelial carcinoma	Morgenstern, Clara
42	Investigating Sex-Specific Transcriptional Differences in Urothelial Bladder Cancer	Myumyun, Ayse Nur
43	Genomic characterization of upper urinary tract urothelial carcinoma and clonal evolution of intravesical recurrence	Nakauma-González, Alberto
44	Adenoviral replication does not require progression into cellular S-phase	Nawroth, Roman
45	Enhancing Oncolytic Adenovirus Efficacy in Tumor Cells through Alpha-Fetoprotein Peptide-Mediated Targeting and Internalization	Nawroth, Roman
46	CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and includes a multistep molecular response	Nawroth, Roman
47	Lymphatic sealing with titanium clips versus ultrasonic dissector during pelvic lymph node dissection at the time of radical cystectomy: A prospective, randomized trial	Nayak, Brusabhanu
48	Lynch Syndrome-Associated Urothelial Cancer: Distinct Genomic Landscape, Constrained Hypermutation, and Preliminary Results from the LS-URO Urine Tumor DNA Screening Study	Nikkola, Jussi
49	Implications of Gemcitabine-Cisplatin therapy on bladder cancer responsiveness to ADCs	Nössing, Christoph
50	Stromal Transcriptomic Signatures are Prognostic in High-Risk Non-Muscle Invasive Bladder Cancer treated with Intravesical Bacillus Calmette-Guerin	Packiam, Vignesh
51	Predicting Response to Intravesical Bacillus Calmette-Guerin Versus Gem/Doce for High-grade Non-muscle-invasive Bladder Cancer	Packiam, Vignesh
52	Non-invasive urine genomic profiling in patients with upper tract urothelial carcinoma	Pallauf, Maximilian
53	Targeting Compensatory DNA Repair Pathways to Restore ATR Inhibitor Sensitivity in Squamous Cell Carcinoma of the Bladder	Pannhausen, Julia
54	The Added Prognostic Value of the UROMOL Classification to the 2021 EAU Risk Stratification in Patients with Non-Muscle-Invasive Bladder Cancer in the COBLAnCE Cohort	Paper, Laura
55	Circulating immune-biomarkers of response to neoadjuvant Sacituzumab Govitecan (SG) alone and with pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC): secondary analyses from SURE-01 and SURE-02 trials	Pastorino, Giovanni Luigi
56	The Role of CCL2 in Bladder Cancer Progression and Metastasis: A Context-Dependent Effect	Pérez-Escavy, Mercedes
57	ABCG2-Mediated SN-38 Efflux Drives Payload-specific Resistance to Sacituzumab Govitecan in Urothelial Carcinoma	Prantl, Isabella
58	The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer	Putluri, Nagireddy
59	Comprehensive Analysis of the Resistance Mechanisms against the Antibody Drug Conjugate Enfortumab Vedotin and its Cytotoxic Payload MMAE in Preclinical Urothelial Carcinoma Models	Rupp, Luis
60	Evaluating the roles of HAI-1 and ST14 in various cellular processes of bladder cancer cell lines	Saeed, Azad
61	Integrated multi-omics analysis of primary and PDX MIBC models suggests targetable molecular vulnerabilities	Saltzman, Alexander



# IBCN2025

October 9 – October 11

Munich, Germany

Poster #	Abstract Title	Presenter
62	Discriminative capacity of the AUA/SUFU hematuria guideline 2025 update – How much progress?	Schmitz-Dräger, Bernd J.
63	Clinical applicability of an mRNA based urine test (Xpert® Bladder Cancer Detection*) for the detection of bladder cancer in patients with microhematuria	Schmitz-Dräger, Bernd J.
64	Final results of the prospective randomized UroFollow trial comparing marker-guided versus cystoscopy-based surveillance in patients with low/intermediate risk bladder cancer	Schmitz-Dräger, Bernd J.
65	Reduce length of hospital stay with the use of methylnaltrexone in radical cystectomy peri-operative; a retrospective study	St-Laurent, Marie-Pier
66	Evaluating the prognostic utility of circulating tumour DNA in metastatic urothelial cancer	Stephenson, Maria
67	Microbiome Immunogenicity in Bladder Cancer	Suleja, Agata
68	Clinical outcomes from 2020 EAU primary High-risk NMIBC patients treated with BCG by 2021 EAU risk classification	Tian, Ye
69	Physical activity before radical cystectomy – the PRACTICE trial: preliminary data	Volz, Yannic
70	Cost of care and oncologic outcomes associated with Blue Light Cystoscopy in an equal setting: results from the BRAVO Trial	Williams, Stephen
71	Quantitative Outcome-Based Grading for Whole Slide NMIBC Images	Yach, Evelyn
72	Differential KLF5 Isoform Usage in Non-Muscle Invasive Bladder Cancer (NMIBC)	Yukse Tekben, Esra Hilal
73	SPP1 protein mediates resistance to neoadjuvant chemotherapy in non-urothelial-like MIBC subtypes	Zadoroznyj, Aymeric
74	Liquid Biopsy Guided Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study	Zhang, Ruiyun
75	Identifying Indolent Low Grade and Aggressive High Grade NMIBC: A Quantitative Grading Framework	Zhang, Taylor
76	Spatial Profiling of the Tumor Immune Microenvironment in Muscle-Invasive Bladder Cancer TREATED WITH Neoadjuvant Platinum Chemotherapy	Zheng, Nicolas

